Prader-willi syndrome
Drug research and approvals for prader-willi syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 14 studies of prader-willi syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 2 approved and 15 open orphan designations naming it.
- Recruiting worldwide: 14
- Trials authorized in Canada: 7
- FDA orphan approvals: 2
- EU medicines: 0
Recruiting Now
Newest start dates first, of 14 recruiting on ClinicalTrials.gov ↗- Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion DysregulationNCT07607730 · Not applicable · Children's Mercy Hospital Kansas City · starts Jan 1, 2027
- A Study of CSTI-500 in Patients With Prader-Willi SyndromeNCT07348601 · Phase 2 · ConSynance Therapeutics · starts May 18, 2026
- Tirzepatide in PWS, HO and GNSONCT06901245 · Phase 4 · Grace Kim · starts May 1, 2025
- Autistic Symptomatology and Sensory Profile in Children With Prader-Willi SyndromeNCT06877715 · Not reported · University Hospital, Toulouse · starts Apr 7, 2025
- Physical Activity and Community EmPOWERment ProjectNCT06740162 · Not applicable · University of North Carolina, Chapel Hill · starts Jan 10, 2025
- Institutional Registry of Rare DiseasesNCT06573723 · Not reported · Hospital Italiano de Buenos Aires · starts Jul 1, 2024
- A Study of Pitolisant in Patients With Prader-Willi SyndromeNCT06366464 · Phase 3 · Harmony Biosciences Management, Inc. · starts May 28, 2024
- Oromyofunctional Therapy: a Rehabilitation Program for OSA in Children With Down Syndrome and Prader-Willi SyndromeNCT07122505 · Not applicable · University Ghent · starts Apr 15, 2024
- Effects of Transcutaneous Vagus Nerve Stimulation on Emotion Regulation and Executive Functioning in Prader-Willi…NCT06720571 · Not applicable · University of Bordeaux · starts Nov 22, 2023
- Cerebellar TMS and Satiety in Prader-Willi SyndromeNCT05938543 · Not applicable · Brigham and Women's Hospital · starts Sep 1, 2023
Trials Authorized in Canada
Newest first; search them all in Canada trials| Oct 24, 2025 | A phase 3, randomized, double-blind, placebo-controlled study of ard-101 for the treatment of hyperphagia in patients with prader -willi syndromeARD-101 | AARDVARK THERAPEUTICS INC | Closed |
| Apr 24, 2025 | A phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of pitolisant followed by an open-label extension in patients with…PITOLISANT (HBS-101) | HARMONY BIOSCIENCES MANAGEMENT, INC. | Ongoing |
| Sep 14, 2023 | A long-term, open-label extension study of carbetocin nasal spray for the treatment of hyperphagia in prader-willi syndromeCARBETOCIN (ACP-101) | ACADIA Pharmaceuticals | Closed |
| Sep 14, 2023 | A phase 3, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in prader-willi…CARBETOCIN (ACP-101) | ACADIA Pharmaceuticals | Closed |
| May 26, 2022 | A phase 2/3, randomized, double-blind, placebo-controlled study of rad011 (cannabidiol oral solution) for the treatment of patients with prader-willi syndromeCANNABIDIOL (RAD011) | Radius Pharms | Pending |
| Dec 7, 2018 | Phase 3, randomized, double-blind, placebo-controlled, 8-week clinical study to assess the efficacy, safety, and tolerability, of intranasal carbetocin…CARBETOCIN (LV-101) | LEVO THERAPEUTICS INC | Closed |
| Aug 28, 2017 | A phase 2 study to evaluate efficacy, safety, and pharmacokinetics of glwl 01 in the treatment of patients with prader willi syndromeGLWL-01 | GLWL RESEARCH INC | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 17| Mar 26, 2025 | Vykat XRtreatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS) | Soleno Therapeutics, Inc. | Approved |
| Jun 20, 2000 | GenotropinLong-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS). | Pharmacia & Upjohn | Approved |
| Apr 10, 2024 | celastroltreatment of Prader-Willi syndrome | ERX Pharmaceuticals, Inc. | Designated |
| Feb 12, 2024 | pitolisantTreatment of Prader-Willi syndrome (PWS) | Harmony Biosciences, LLC | Designated |
| Jan 30, 2024 | 5-BROMO-N-(PROP-2-YN-1-YL)-2-(1H-1,2,4-TRIAZOL-1-YL)…treatment of Prader-Willi syndrome | Palobiofarma S.L. | Designated |
| May 16, 2023 | avasimibeTreatment of Prader-Willi syndrome | EFIL BioScience Inc. | Designated |
| Jan 3, 2023 | Cannabidiol acid methyl ester (CBDA-ME)Treatment of Prader-Willi Syndrome | EPM Group Inc. | Designated |
| Mar 1, 2022 | OxytocinTreatment of Prader-Willi Syndrome | Tonix Pharmaceuticals, Inc. | Designated |
| Sep 2, 2021 | Synthetic analogue of cyclic Glycine-ProlineTreatment of Prader-Willi Syndrome | Neuren Pharmaceuticals, Ltd. | Designated |
| Mar 2, 2021 | Tesofensine plus metoprolol in a fixed-dose combinationTreatment of Prader-Willi Syndrome | Saniona S/A | Designated |
| Oct 12, 2017 | synthetic cyclic 8 amino acid analog of human unacylated…Treatment of Prader-Willi syndrome (PWS) | Millendo Therapeutics, Inc. | Designated |
| Jun 15, 2017 | oxytocinTreatment of Prader-Willi syndrome | Eric Hollander, MD | Designated |
| Jun 8, 2017 | OleoylethanolamideTreatment of Prader-Willi syndrome | NutriForward, LLC | Designated |
| Jan 19, 2017 | D-tagatoseTreatment of Prader-Willi Syndrome | Biospherics.net LLC | Designated |
| Sep 21, 2015 | setmelanotideTreatment of Prader-Willi Syndrome. | Rhythm Metabolics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA